Policy Briefs
S&T Policy Brief
In recent years, both Europe and China have made significant investments in personalised medicine research and development, making them key players in driving innovation in this field.
This policy brief explores the potential for cooperation between Europe and China in advancing personalised medicine. It examines the current state of personalised medicine R&D in both regions, highlighting strengths and areas for improvement. In addition, the brief outlines the benefits of increased collaboration between Europe and China in personalised medicine. It also identifies key challenges and barriers to collaboration.
Finally, the policy brief provides recommendations for policy makers and researchers on how to enhance cooperation between Europe and China in the field of personalised medicine.
ELSA Policy Brief
The cooperation between Europe and China in personalised medicine has the potential to significantly advance patient care and healthcare outcomes. However, several ethical, legal, and social challenges must be addressed to ensure the responsible and ethical implementation of personalised medicine practices.
This policy brief provides an overview of the key ethical, legal, and social aspects that need to be considered in the cooperation between Europe and China in personalised medicine. It also gives recommendations to ensure that personalised medicine benefits patients, healthcare providers, and society as a whole.